BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 7920221)

  • 1. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
    Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
    Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group.
    Milano G; Thyss A; Serre Debeauvais F; Laureys G; Benoit Y; Deville A; Dutour C; Robert A; Otten J; Behar C
    Eur J Cancer; 1990 Apr; 26(4):492-5. PubMed ID: 2141516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
    J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
    Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
    J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.
    Vassal G; Valteau D; Bonnay M; Patte C; Aubier F; Lemerle J
    Pediatr Hematol Oncol; 1990; 7(1):71-7. PubMed ID: 2397170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
    Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
    Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.
    Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L
    J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
    Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
    Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
    Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
    Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
    Schmiegelow K; Ifversen M
    Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.
    Borsi JD; Sagen E; Romslo I; Slørdal L; Moe PJ
    Cancer Chemother Pharmacol; 1990; 27(2):164-7. PubMed ID: 2249335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
    Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
    J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
    Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.
    Tetef ML; Margolin KA; Doroshow JH; Akman S; Leong LA; Morgan RJ; Raschko JW; Slatkin N; Somlo G; Longmate JA; Carroll MI; Newman EM
    Cancer Chemother Pharmacol; 2000; 46(1):19-26. PubMed ID: 10912573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.